|Bid||4.6800 x N/A|
|Ask||4.8600 x N/A|
|Day's Range||4.7800 - 4.7800|
|52 Week Range||2.9000 - 5.3500|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for 6IB.MU
0734 GMT – Innovent Biologics ’ earnings may be hit by some developments including delays in general procurement from Chinese hospitals starting 3Q, owing to a change in sentiment toward ambitious marketing by drugmakers, CCB International Securities analysts say in a research report. After factoring in the biotech company’s recent capital-raising and boosting the brokerage’s research & development cost estimates for 2023-2025, CCB International Securities lifts its 2023 and 2024 net-loss forecasts for Innovent Biologics by 7% and 70%, respectively. Its forecast of a net profit in 2025 also changes to a projection of a net loss, adds the brokerage, which cuts the stock’s target price to HK$44.50 from HK$47.00 with an unchanged outperform rating.
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and other major diseases, announces its 2023 interim results and major company business updates.
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announces that China's National Medical Products Administration (NMPA) has approved SINTBILO® (tafolecimab injection, anti-PCSK9 monoclonal antibody) for the treatment of adult patients with primary hypercholesterolemia (including heterozygous